GlobeNewswire

YD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness Programs

GlobeNewswire

TAIPEI, Taiwan, and BOTHELL, Wash., Oct. 20, 2026 -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection and ophthalmologic innovations, today announced a strategic collaboration with EG BioMed Co., Ltd., a Taiwan registered company and an affiliate of YD Bio (“EG BioMed”), and digital health provider JoiiUp. The partnership integrates an AI Cancer Risk Assessment (the “Assessment”), jointly developed by YD Bio and EG BioMed, into JoiiUp’s JoiiSports app, expanding access to personalized health insights for corporate wellness programs and healthcare institutions.